MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer

MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer

Summary: Advanced prostate cancers are treated with therapies targeting the androgen receptor (AR) signaling pathway. While many tumors initially respond to AR inhibition, nearly all develop resistance. It is critical to understand how prostate tumor cells respond to AR inhibition in order to exploi...

詳細記述

書誌詳細
主要な著者: Preston D. Crowell, Jenna M. Giafaglione, Anthony E. Jones, Nicholas M. Nunley, Takao Hashimoto, Amelie M.L. Delcourt, Anton Petcherski, Raag Agrawal, Matthew J. Bernard, Johnny A. Diaz, Kylie Y. Heering, Rong Rong Huang, Jin-Yih Low, Nedas Matulionis, Nora M. Navone, Huihui Ye, Amina Zoubeidi, Heather R. Christofk, Matthew B. Rettig, Robert E. Reiter, Michael C. Haffner, Paul C. Boutros, Orian S. Shirihai, Ajit S. Divakaruni, Andrew S. Goldstein
フォーマット: 論文
言語:English
出版事項: Elsevier 2023-10-01
シリーズ:Cell Reports
主題:
CP: Cancer
CP: Metabolism
オンライン･アクセス:http://www.sciencedirect.com/science/article/pii/S2211124723012330

インターネット

http://www.sciencedirect.com/science/article/pii/S2211124723012330

類似資料